• 2-APB as a Causal Probe of ER Calcium Stress

  2026-10-01

  2-APB (2-aminoethoxydiphenyl borate) is more than an IP3R antagonist: it can function as a causal probe for separating ER calcium release, protease activation, autophagy, and apoptosis. This article translates recent Bombyx mori findings into a practical framework for calcium signaling, SOCE, and stress-injury experiments.

• Niclosamide Workflows for STAT3 Cancer Research

  2026-10-01

  Build mechanism-first cancer research workflows around Niclosamide, connecting STAT3 Tyr-705 inhibition with apoptosis, cell-cycle profiling, and NF-κB pathway analysis. Practical dosing, solubility, controls, and troubleshooting guidance help distinguish pathway engagement from nonspecific cytotoxicity.

• Hydrocortisone in EMT and Splicing Assays

  2026-09-30

  Hydrocortisone is more than a glucocorticoid hormone reference compound: in epithelial culture, it can be an important background variable when interpreting EMT and alternative-splicing phenotypes. This guide connects B1951 handling with the DAPK3–TIA1–CLSTN1 metastasis axis and practical assay controls.

• Mdivi-1: Selective DRP1 Inhibitor Guide

  2026-09-30

  Mdivi-1 is a cell-permeable selective DRP1 inhibitor used to investigate mitochondrial fission, apoptosis, and tissue injury. This guide connects its reported mechanism and experimental parameters with current evidence on mitochondrial dynamics and ECM–mitochondria signaling.

• ALC-0159: Designing the Next mRNA LNP Logic

  2026-09-29

  ALC-0159 is best understood not as a standalone efficacy driver, but as a PEG-conjugated lipid excipient within a system whose surface behavior, endosomal biology, and tolerability must be optimized together. New evidence on membrane-destabilizing zwitterionic lipids provides a useful framework for deciding how established formulation components can support the next generation of mRNA delivery platforms.

• MLN2238 Proteasome β5 Inhibitor Workflow

  2026-09-29

  MLN2238 gives researchers a reversible, highly potent way to separate β5-driven proteasome stress from broader catalytic-site inhibition in cancer and proteostasis models. This workflow connects dose-controlled target engagement with apoptosis, ROS–JNK–CREB signaling, drug-resistance testing, and practical formulation guidance.

• Candida krusei Forms Trigger Distinct BMEC Apoptosis

  2026-09-28

  Miao et al. show that the yeast and hypha phases of Candida krusei both induce apoptosis in bovine mammary epithelial cells, but engage different dominant pathways. The study combines orthogonal cell-death assays with signaling analysis, providing a useful framework for distinguishing morphotype-specific host responses in fungal mastitis.

• Phenytoin Assay Design: Separating Channel and Enzyme Effect

  2026-09-28

  Phenytoin research requires careful separation of neuronal sodium-channel effects from biochemical assay findings. This guide interprets published paraoxonase-1 inhibition data, explains their limits, and outlines practical choices for concentration planning, controls, and compound handling.

• 3-Aminobenzamide (PARP-IN-1): Evidence & Use

  2026-09-27

  3-Aminobenzamide (PARP-IN-1) is a PARP inhibitor reported to have an approximately 50 nM IC50 in CHO cells. Research applications span oxidative-stress and diabetic-nephropathy models, while coronavirus studies provide a separate rationale for investigating PARP biology—not proof that this compound has antiviral activity.

• Charge-Reversed Exosomes for Cartilage mRNA Delivery

  2026-09-26

  Zhang and colleagues engineered cationic, charge-reversed exosomes to move reporter mRNA through the negatively charged cartilage matrix, a barrier that limits conventional delivery. The study reports deeper cartilage penetration and chondrocyte EGFP expression than with native exosomes, while leaving therapeutic efficacy and long-term safety for future testing.

• Mdivi-1 Workflows for Mitochondrial Fission Research

  2026-09-25

  Use Mdivi-1 to test how mitochondrial fission contributes to hypoxia-associated apoptosis, while pairing drug treatment with mitochondrial, cell-death, and microbiome readouts. A practical workflow separates product-recommended starting conditions from study-specific details that must be verified in the full methods.

• Sex Differences in Angiotensin II Hypertension

  2026-09-25

  Xue and colleagues used telemetry in conscious mice to show that chronic angiotensin II produced a substantially larger blood-pressure rise in intact males than females, with gonadectomy shifting the response in opposite directions by sex. Their measurements also connect the pressure phenotype to altered baroreflex control and a larger ganglionic-blockade-sensitive component in males, while leaving the precise hormonal and neural mechanisms unresolved.

• Caspase-3–NDUFS1 Axis in Trichothecene Liver ROS

  2026-09-24

  A non-peer-reviewed preprint proposes that caspase-3 cleavage of the complex I subunit NDUFS1 amplifies mitochondrial ROS after DON and T-2 toxin exposure, while ER-localized ERO1α contributes a second source of oxidative stress. The findings suggest a connected mitochondrial–ER redox response and identify experiments that can test its contribution to liver-cell injury.

• TNF-alpha Recombinant Murine Protein in Death Assays

  2026-09-24

  Learn how TNF-alpha recombinant murine protein can help distinguish receptor-driven cell death from RNA Pol II degradation-dependent apoptosis. This assay-focused guide translates recent mechanistic findings into practical controls, interpretation rules, and product-handling considerations.

• Gastrin I (human): Reliable Assay Workflows

  2026-09-23

  Practical guidance for using Gastrin I (human), SKU B5358, in receptor-focused gastric physiology experiments and interpreting cell-based assay results. Covers peptide handling, vehicle controls, workflow parameters, model limitations, and evidence-based product selection.

8097 records 1/540 page Next 12345 下5页 Last page